Expression of interferon receptor genes (IFNAR1 and IFNAR2 mRNA) in the liver may predict outcome after interferon therapy in patients with chronic genotype 2a or 2b hepatitis C virus infection

Journal of Clinical Gastroenterology

Volumn 26, Issue 2, 1998, Pages 135-140

  Morita, Katsumi ^a   Tanaka, Katsuaki ^a   Saito, Satoru ^a   Kitamura, Takehiko ^a   Kondo, Masaaki ^a   Sakaguchi, Takashi ^a   Morimoto, Manabu ^a   Sekihara, Hisahiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Interferon receptor; mRNA; Polymerase chain reaction

Indexed keywords

ALPHA INTERFERON; INTERFERON RECEPTOR; LYMPHOBLAST INTERFERON; MESSENGER RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HUMAN; LIVER BIOPSY; MALE; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; RETROSPECTIVE STUDIES; RNA, MESSENGER; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0031944679     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199803000-00010     Document Type: Article

References (37)

1. Ku G, Choo QL, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
3. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439-62.
4. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575-8.
5. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
6. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
7. Tiné F, Magrin S, Craxí A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-9.
8. Marcellin P, Boyer N, Giostra E, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
9. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993;104:877-83.
10. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
11. Chayama K, Tsubota A, Arase Y, et al. Genotype, slow decrease in virus tiler during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 1995;23:648-53.
12. Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
13. Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
14. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon α2a therapy. J Med Virol 1995;46:162-8.
15. 125I-labelled mouse interferon to a specific cell surface receptor. Nature 1980;284:459-61.
16. Pestka S, Lauger JA, Zoon KC, Samnel CE. Interferon receptors. Anmi Rev Biochem 1987;56:740-51.
17. Colamonici OR, Pfeffer LM, D'alessandro F, et al. Multichain structure of the IFN-α receptor on hematopoietic cells. J Immunol 1992;148:2126-32.
18. Branca AA, Baglioni C. Evidence that types I and II interferons have different receptors. Nature 1981;294:768-70.
19. Colamonici OR, Domanski P. Identification of a novel subunit of the type I interferon receptor localized to human chromosome 21. J Biol Chem 1993;268:10895-9.
20. Uzé G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon α receptor into mouse cells: cloning and expression of its cDNA. Cell 1990;60:225-34.
21. Novick D, Cohen B, Rubinstein M. The human interferon α/β receptor: characterization and molecular cloning. Cell 1994;77:391-400.
22. Lutfalla G, Holland SJ, Cinato E, et al. Mutant U5A cells are complemented by an interferon-α β receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 1995;14:5100-8.
23. Fukuda R, Ishimura N, Ishihara S, et al. Expression of interferon-alpha receptor mRNA in the liver in chronic liver disease associated with hepatitis C virus: relation to effectiveness of interferon therapy. J Gastroenterol 1996;31:806-11.
24. Fukuda R, Ishimura N, Kushiyama Y, et al. Effectiveness of interferon-alpha therapy in chronic hepatitis C is associated with the amount of interferon-alpha receptor mRNA in the liver. J Hepatol 1997;26:455-61.
25. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73:673-9.
26. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
27. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A 1989;86:6230-4.
28. Kondo M, Tanaka K, Ikeda M, et al. Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996;11:236-40.
29. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339:237-8.
30. Gilliland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990;87:2725-9.
31. Groote DJ, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;2:626-8.
32. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
33. Lau JYN, Sheron N, Morris AG, Bomford AB, Alexander GJM, Williams R. Interferon-α receptor expression and regulation in chronic hepatitis B virus infection. Hepatology 1991;13:332-8.
34. 2a receptor by interferon-γ. Journal of Pharmacobiodynamics 1989;12:299-304.
35. Chomarat P, Rissoan MC, Banchereau J, Miossec P. Interferon γ inhibits interleukin 10 production by monocytes. J Exp Med 1993;177:523-7.
36. + natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol 1993;23:1831-8.
37. Pace JL, Russell SW, Schreiber RD, Altman A, Katz DH. Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-γ. Proc Natl Acad Sci U S A 1983;80:3782-6.